Physician profile
Mark T Schroeder
NPI 1952492506
$235.28
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $84.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $84.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.61 | 2019 | |
| Celgene Corporation | $18.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.35 | 2019 | |
| Amgen INC. | $14.69 | 2019 | |
| Lilly USA, LLC | $14.34 | 2019 | |
| Genentech USA, INC. | $14.24 | 2019 | |
| Exelixis INC. | $13.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.53 | 2019 | |
| Octapharma USA, INC. | $12.05 | 2019 | |
| Janssen Biotech, INC. | $10.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.